

Benjamin T Diamond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6529703/publications.pdf>

Version: 2024-02-01

29
papers

607
citations

758635

12
h-index

642321

23
g-index

33
all docs

33
docs citations

33
times ranked

948
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. <i>Seminars in Oncology</i> , 2022, , .	0.8	1
2	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Clinical Cancer Research</i> , 2021, 27, 2111-2118.	3.2	5
3	Positive selection as the unifying force for clonal evolution in multiple myeloma. <i>Leukemia</i> , 2021, 35, 1511-1515.	3.3	10
4	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 181-199.	1.2	19
5	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. <i>Nature Communications</i> , 2021, 12, 1861.	5.8	68
6	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€mg/m ²) in combination with lenalidomide and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E193-E196.	2.0	10
7	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.3	12
8	The mutagenic impact of melphalan in multiple myeloma. <i>Leukemia</i> , 2021, 35, 2145-2150.	3.3	32
9	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141.	0.5	7
10	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , the, 2021, 8, e422-e432.	2.2	50
11	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. <i>Leukemia</i> , 2021, , .	3.3	8
12	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	3.4	63
13	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5172.	5.8	27
14	<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). <i>Haematologica</i> , 2021, 106, 2918-2926.	1.7	18
15	Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101140.	0.7	9
16	Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. <i>Leukemia</i> , 2020, 34, 1476-1480.	3.3	39
17	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	5.8	41
18	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46

#	ARTICLE	IF	CITATIONS
19	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	2.6	81
20	Second malignancies in multiple myeloma; emerging patterns and future directions. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101144.	0.7	27
21	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive <i><i>Versus</i></i> Stable Myeloma Precursor Disease. <i>Blood</i> , 2020, 136, 47-48.	0.6	2
22	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
23	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
24	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	0.6	1
25	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. <i>Blood</i> , 2020, 136, 10-10.	0.6	1
26	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Blood</i> , 2020, 136, 50-51.	0.6	0
27	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 52-53.	0.6	2
28	Duration of Post-Autologous Hematopoietic Cell Transplant Anemia and Thrombocytopenia Are Associated with Prolonged Hospital Length-of-Stay for Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
29	Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 613-626.	0.9	8